When news of US President Donald Trump’s positive COVID-19 test broke on the 24-hour news cycle in the wee hours of Friday morning, mainstream media scrambled for details about when he tested positive, severity of his case, and particulars of his treatment plan. Press conferences by doctors at Walter Reed National Military Medical Center (WRMC, the hospital Trump was whisked away to) and tweets from the Commander in Chief led to as much confusion as they did clarity, with initial announcements being later corrected by subsequent statements.
However, reports coming from the White House, Trump’s personal doctor, and WRMC spokespeople appear to converge on the president’s treatment strategy including three specific therapies:
- Remdesivir, an antiviral
- Dexamethasone, an anti-inflammatory
- REGN-COV2, an antibody cocktail from Regeneron.
To date, there are no drugs approved by the US Food and Drug Administration (FDA) to treat and/or cure the virus, although Regeneron is one of the antibody cocktails in the running as a hopeful therapy (another being a similar product from Lilly).
The following are the latest articles from Outsourcing-Pharma and BioPharma-Reporter on the drugs reportedly given to Trump in an attempt to get a handle on his COVID-19 case and varying symptoms.
Remdesivir
Hovione to boost output of COVID-19 treatment excipient
FHI Clinical to support ACTT remdesivir trial for COVID-19
Gilead gets green light for inhaled remdesivir study
Gilead, Cipla partner on remdesivir expansion
Dexamethasone
Novartis launches NFP portfolio of COVID-19 treatments
AI Vivo: dexamethasone shows promise as COVID-19 treatment
REGN-COV2
Roche, Regeneron ally to triple supply of COVID-19 antibody cocktail
Regeneron targets September data drop from COVID-19 antibody trial
Regeneron COVID-19 antibody cocktail enters late-stage trials
Regeneron devotes New York facility to COVID-19 cocktail treatment
Our editors will continue to monitor the situation and offer updates as they become available.
